Case Reports in Hematology

Case Reports in Hematology / 2018 / Article

Case Report | Open Access

Volume 2018 |Article ID 7863943 |

Kosuke Miki, Naoshi Obara, Kenichi Makishima, Tatsuhiro Sakamoto, Manabu Kusakabe, Takayasu Kato, Naoki Kurita, Hidekazu Nishikii, Yasuhisa Yokoyama, Mamiko Sakata-Yanagimoto, Yuichi Hasegawa, Shigeru Chiba, "An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature", Case Reports in Hematology, vol. 2018, Article ID 7863943, 5 pages, 2018.

An Unprecedented Case of p190 BCR-ABL Chronic Myeloid Leukemia Diagnosed during Treatment for Multiple Myeloma: A Case Report and Review of the Literature

Academic Editor: Massimo Breccia
Received19 Aug 2018
Accepted26 Sep 2018
Published10 Oct 2018


We report the case of a 76-year-old man who was diagnosed as having chronic myeloid leukemia (CML) with p190 BCR-ABL while receiving treatment for symptomatic multiple myeloma (MM). The diagnosis of MM was based on the presence of serum M-protein, abnormal plasma cells in the bone marrow, and lytic bone lesions. The patient achieved a partial response to lenalidomide and dexamethasone treatment. However, 2 years after the diagnosis of MM, the patient developed leukocytosis with granulocytosis, anemia, and thrombocytopenia. Bone marrow examination revealed Philadelphia chromosomes and chimeric p190 BCR-ABL mRNA. Fluorescence in situ hybridization also revealed BCR-ABL-positive neutrophils in the peripheral blood, which suggested the emergence of CML with p190 BCR-ABL. The codevelopment of MM and CML is very rare, and this is the first report describing p190 BCR-ABL-type CML coexisting with MM. Moreover, we have reviewed the literature regarding the coexistence of these diseases.

1. Introduction

Multiple myeloma (MM) is a lymphoid cancer that is characterized by monoclonal proliferation of malignant plasma cells in the bone marrow, monoclonal protein in the serum, and organ dysfunction [1]. Chronic myeloid leukemia (CML) is a clonal disorder of myeloid origin that is characterized by the Philadelphia chromosome, t(9; 22) (q34; q11), in which the BCR-ABL fusion gene is created. Several types of BCR-ABL are known, with the p210 and p190 types being the most common, distinguished by the break point in the BCR gene. The vast majority of CML cases result from the p210-type of BCR-ABL, while the p190-type is rarely found in CML [2]. The coexistence of MM and CML in the same patient is rare, with only 22 reported cases [323], all involving p210 BCR-ABL. Therefore, we report a case of coexisting MM and CML with p190 BCR-ABL. Given the rarity of this case, we also discuss the origins of these hematologic malignancies and review the relevant literature.

2. Case Report

A 76-year-old man was referred to our hospital in September 201X, because of right leg pain, lower back pain, and weight loss of 3 kg. Lumbar magnetic resonance imaging and computed tomography (CT) suggested the presence of lumbar spinal canal stenosis and a sacral tumor (Figure 1(a)). Laboratory testing revealed a markedly elevated serum IgG level (5,436 mg/dL, normal: 800–1,800 mg/dL) and an elevated serum beta-2 microglobulin level (4.1 µg/mL, normal: 0–3 µg/mL), although there were no signs of anemia, renal dysfunction, or proteinuria. Serum immunofixation revealed IgGκ-type M-protein, with an estimated serum-free κ and λ chain ratio of 21.5 : 1 (Figure 1(b)). Microscopic examination and flow cytometric analysis of bone marrow aspirate revealed elevated numbers of CD138-positive abnormal plasma cells. Cytogenetic analysis of the bone marrow revealed 46XY, and the patient was diagnosed as having MM (R-ISS, stage II). Chimeric p190 BCR-ABL mRNA was not detected in the bone marrow sample at this point. The patient underwent two cycles of bortezomib plus dexamethasone and two cycles of cyclophosphamide, bortezomib, and dexamethasone (CBD) but did not respond to either treatment regimen. The treatment was switched to lenalidomide (25 mg/day) plus dexamethasone (20 mg/week; Ld therapy), and there was a marked response, with a substantial decrease in the M-protein and disappearance of the sacral tumor on CT. After 24 cycles of Ld therapy, the patient achieved a partial response based on the International Myeloma Working Group criteria.

In December 201X+2, the patient developed leukocytosis (white blood cell count: 35.8 × 109/L) and thrombocytopenia (platelet count: 3 × 109/L). Bone marrow biopsy and aspiration revealed hypercellularity with a marked increase in myeloid lineage cells but without an increase in blast cells (4%). Cytogenetic analysis revealed 46XY t(9; 22) (q34; q11.2) in 20 of 20 cells, and fluorescence in situ hybridization (FISH) analysis revealed that 99.5% of the cells were positive for BCR-ABL. Peripheral blood neutrophils were also positive for BCR-ABL (98.8%) (Figures 2(a)2(b)). Chimeric p190, but not p210, BCR-ABL mRNA was detected by using polymerase chain reaction (Figure 2(c)). The diagnosis was confirmed to be CML with p190 BCR-ABL in the accelerated phase (AP), which coexisted with MM (a maintained partial response). Dasatinib treatment (100 mg/day) was started immediately. The dose was subsequently decreased to 50 mg/day, due to the persistence of thrombocytopenia. In April 201X+3, a bone marrow examination indicated that the patient had achieved a second chronic phase, with 31% of this cells being positive for BCR-ABL upon FISH analysis, and that his peripheral blood count had normalized. However, 5 months later, FISH analysis revealed that 85.8% of his bone marrow cells were positive for BCR-ABL, and subsequently, his treatment was changed from dasatinib to bosutinib. This switch appeared to be ineffective, as no decrease in the BCR-ABL-positive bone marrow cells was detected after 2 months.

3. Discussion

There have only been 24 cases of coexisting MM and CML reported (Table 1) [325]. MM and CML were diagnosed simultaneously in 9 cases, and the diagnoses were sequential in the remaining cases, with MM being diagnosed first in 8 cases and CML being diagnosed first in 7 cases. Among the previous reports, all genotypes confirmed by PCR were p210-CML in patients with coexisting MM and CML. Our case is the first reported of MM coexisting with p190-CML in the same patient. The intervals between the sequential diagnoses ranged from 3 months to 120 months. Multiple possibilities could be considered regarding the association between MM and CML. First, these two malignancies could occur independently, and their coexistence, while very rare, could be simply coincidence. Second, common precursors, referred to as “clonal hematopoiesis of indeterminate potential (CHIP),” give rise to both MM and CML cells in a patient. Given our patient’s relatively advanced age, it is possible that CHIP had a common origin, although we have no direct evidence to support this possibility. A third possible explanation is that the second disease might be a therapy-related malignancy that develops after treatment for the first disease. In the present case, the diagnosis of MM was followed by that of CML. The frequency of secondary carcinogenesis in patients with MM was evaluated for cohorts participating in clinical trials with lenalidomide, which were conducted from 2000 through 2012 [24]. This report showed that the incidence of secondary hematologic malignancies was increased in patients who concurrently received melphalan and lenalidomide, while it did not increase in those receiving other treatment protocols, regardless of whether lenalidomide was included [26]. There is no clear evidence that lenalidomide is carcinogenic, and there has only been one reported case of CML that developed after lenalidomide treatment. Therefore, the increased incidence of hematologic malignancies has been attributed to melphalan, because alkylating agents such as melphalan are known to cause therapy-related myelodysplastic syndromes. According to previous case reports of MM coexisting with CML, many patients received alkylating agents as treatment for MM (Table 1). In the present case, a small dose of an alkylating agent (cyclophosphamide; total: 2,400 mg/m2) was administered during two cycles of CBD therapy. We, therefore, needed to consider the possibility that the cyclophosphamide treatment caused the CML. However, an accumulation of case reports and further investigations are required to draw definitive conclusions.

PtAge/SexYearFirst diseaseDiagnosis interval (month)Type of M-proteinTherapy for MMTherapy for CMLConfirmation method of Ph+Type of PhReference

177M1972MM33BJPNo treatmentNo treatmentChrMacSween and Langley [3]
265/F1974CML113IgG-κNo treatmentBusulfanChrDerghazarian and Whittemore [4]
358/M1982MM and CMLSimultaneousIgG-κMP, RTHU, Busulfan,ChrBoots and Pegrum [5]
471/M1993MM24IgG-κMP, RTHUChrKlenn et al. [6]
572/F1998MM and CMLSimultaneousIgG-κVPIFN-αChr, PCR, FISHP210Tanaka et al. [7]
670/M1999MM33IgG-κNot reportedNot reportedChrNitta et al. [8]
781/M2001MM and CMLSimultaneousIgA-κMPNo treatmentChr, PCRAlvarez-Larrán et al. [9]
866/M2003MM and CMLSimultaneousIgG-κMPINF-α, HU, BusulfanChr, PCR, FISHP210Schwarzmeier et al. [10]
947/M2003MM33BJPLOAD-INNot reportedChrNakagawa [11]
1068/M2005CML20IgG-λMPIFN-α, imatinibChr, PCRP210Garipidou et al. [12]
1185/F2005MM and CMLSimultaneousIgG-λNot reportedNot reportedChr, PCRP210Wakayama et al. [13]
1276/M2009CML14IgA-κMPIFN-α, imatinibChr, PCR, FISHP210Galanopoulos et al. [14]
1357/F2009CML65IgA-κTD, VADImatinibChr, PCRP210Michael et al. [15]
1472/F2010CML3IgG-κNo treatmentImatinibChr, PCRP210Ide et al. [16]
1571/F2012MM and CMLSimultaneousIgG-κMP, Bd, LdImatinibChrOffiah et al. [17]
1664/F2013MM and CMLSimultaneousIgA-κBDImatinibChrRomanenko et al. [18]
1762/F2013MM17IgG-κRT, VCD, VCDD, VRDDasatinibChr, PCRP210Ragupathi et al. [19]
1877/M2014MM and CMLSimultaneousIgG-κRT, BDNo treatmentChr, PCRP210Maerki et al. [20]
1960/M2014MM48IgG-κRT, LdHU, dasatinibChr, FISHAlsidawi et al. [21]
2063/F2012CML120IgG-κBD, LdImatinibChr, PCRP210Pessach et al. [22]
2168/M2012MM54IgG-λVADImatinibChr, PCRP210Pessach et al. [22]
2276/M2015CML38IgA-λNo treatmentImatinibChr, PCRAhn et al. [23]
2351/F2016MMUnknownIgGBDImatinibChr, PCRWolleschak and Heidel [24]
2488/M2016MM and CMLSimultaneousIgD-κVRDImatinibChrAli et al. [25]
2576/M2018MM28IgG-κLdDasatinib, bosutinibChr, PCR, FISHP190Our case

BJP, Bence Jones protein; MP, melphalan, prednisolone; RT, radiation therapy; HU, hydroxyurea; LOAD-IN, melphalan, ranimustine, vincristine, IFN-α; PSL, prednisolone; VCD, bortezomib, cyclophosphamide, dexamethasone; VCDD, VCD plus doxorubicin; VRD, bortezomib, lenalidomide, dexamethasone; Ld, lenalidomide, dexamethasone; VAD, vincristine, doxorubicin, dexamethasone; BD, bortezomib, dexamethasone; CBD, BD plus cyclophosphamide; Rd, lenalidomide, dexamethasone; TD, thalidomide, dexamethasone; Chr, chromosome; PCR, polymerase chain reaction; FISH, fluorescence in situ hybridization.

Although p190 BCR-ABL CML has been reported in 1% of CML cases, there have been several clinical observations suggesting that CML with p190 BCR-ABL is difficult to treat [27]. Furthermore, p190 BCR-ABL has been identified as a marker for high-risk disease, and early stem cell transplantation has been recommended if the patient is eligible [26]. Our patient received initial treatment of dasatinib for his CML in AP with p190 BCR-ABL, which provided a partial cytogenetic response at 4 months after the diagnosis. Although the long-term effects of dasatinib treatment in patients with p190 BCR-ABL CML are unknown, in the present case, the duration of response to dasatinib was relatively short.

Ethical Approval

This study was adhered to the tenets of the Declaration of Helsinki.

Informed consent was obtained from the patient.

Conflicts of Interest

The authors declare that they have no conflicts of interest.


  1. A. Palumbo and K. Anderson, “Multiple myeloma,” New England Journal of Medicine, vol. 364, pp. 1046–1060, 2011. View at: Publisher Site | Google Scholar
  2. W. Al Achkar, A. Wafa, H. Mkrtchyan, F. Moassass, and T. Liehr, “A rare case of chronic myeloid leukemia with secondary chromosomal changes including partial trisomy 17q21 to 17qter and partial monosomy of 16p13.3,” Molecular Cytogenetics, vol. 3, no. 1, 2010. View at: Publisher Site | Google Scholar
  3. J. M. MacSween and G. R. Langley, “Light-chain disease (hypogammaglobulinemia and Bence Jones proteinuria) and sideroblastic anemia-preleukemic chronic granulocytic leukemia,” Canadian Medical Association Journal, vol. 106, no. 9, pp. 995–998, 1972. View at: Google Scholar
  4. C. Derghazarian and N. B. Whittemore, “Multiple myeloma superimposed on chronic myelocytic leukemia,” Canadian Medical Association Journal, vol. 110, no. 9, pp. 1047–1050, 1974. View at: Google Scholar
  5. M. A. Boots and G. D. Pegrum, “Simultaneous presentation of chronic granulocytic leukaemia and multiple myeloma,” Journal of Clinical Pathology, vol. 35, no. 3, pp. 364-365, 1982. View at: Publisher Site | Google Scholar
  6. P. J. Klenn, B. H. Hyun, Y. H. Lee, and W. Y. Zheng, “Multiple myeloma and chronic myelogenous leukemia--a case report with literature review,” Yonsei Medical Journal, vol. 34, no. 3, pp. 293–300, 1993. View at: Publisher Site | Google Scholar
  7. M. Tanaka, R. Kimura, A. Matsutani et al., “Coexistence of chronic myelogenous leukemia and multiple myeloma. Case report and review of the literature,” Acta Haematologica, vol. 99, no. 4, pp. 221–223, 1998. View at: Publisher Site | Google Scholar
  8. M. Nitta, K. Tsuboi, S. Yamashita et al., “Multiple myeloma preceding the development of chronic myelogenous leukemia,” International Journal of Hematology, vol. 69, no. 3, pp. 170–173, 1999. View at: Google Scholar
  9. A. Alvarez-Larrán, M. Rozman, and F. Cervantes, “Simultaneous occurrence of multiple myeloma and chronic myeloid leukemia,” Haematologica, vol. 86, no. 8, p. 894, 2001. View at: Google Scholar
  10. J. D. Schwarzmeier, M. Shehata, J. Ackermann, M. Hilgarth, H. Kaufmann, and J. Drach, “Simultaneous occurrence of chronic myeloid leukemia and multiple myeloma: evaluation by FISH analysis and in vitro expansion of bone marrow cells,” Leukemia, vol. 17, no. 7, pp. 1426–1428, 2003. View at: Publisher Site | Google Scholar
  11. M. Nakagawa, “A case of a 47-year-old man who developed chronic myelogenous leukemia after therapy for multiple myeloma,” Ja Hokkaido Koseiren Obihiro Kosei Hospital, vol. 6, pp. 101–106, 2003. View at: Google Scholar
  12. V. Garipidou, S. Vakalopoulou, and K. Tziomalos, “Development of multiple myeloma in a patient with chronic myeloid leukemia after treatment with imatinib mesylate,” Oncologist, vol. 10, no. 6, pp. 457-458, 2005. View at: Publisher Site | Google Scholar
  13. T. Wakayama, S. Fujita, and H. Ago, “An elder patient coexisted with multiple myeloma and chronic myeloid leukemia before treatments,” Medical Journal of Shimane Prefectural Central Hospital, vol. 29, pp. 63–67, 2005. View at: Google Scholar
  14. A. Galanopoulos, S. I. Papadhimitriou, E. Kritikou-Griva, M. Georgiakaki, and N. I. Anagnostopoulos, “Multiple myeloma developing after imatinib mesylate therapy for chronic myeloid leukemia,” Annals of Hematology, vol. 88, no. 3, pp. 281-282, 2009. View at: Publisher Site | Google Scholar
  15. M. Michael, M. Antoniades, E. Lemesiou, N. Papaminas, and F. Melanthiou, “Development of multiple myeloma in a patient with chronic myeloid leukemia while on treatment with imatinib mesylate for 65 months,” Oncologist, vol. 14, no. 12, pp. 1198–1200, 2009. View at: Publisher Site | Google Scholar
  16. M. Ide, N. Kuwahara, E. Matsuishi, S. Kimura, and H. Gondo, “Uncommon case of chronic myeloid leukemia with multiple myeloma,” International Journal of Hematology, vol. 91, no. 4, pp. 699–704, 2010. View at: Publisher Site | Google Scholar
  17. C. Offiah, J. P. Quinn, P. Thornton, and P. T. Murphy, “Co-existing chronic myeloid leukaemia and multiple myeloma: rapid response to lenalidomide during imatinib treatment,” International Journal of Hematology, vol. 95, no. 4, pp. 451-452, 2012. View at: Publisher Site | Google Scholar
  18. N. A. Romanenko, S. S. Bessmel’tsev, U.’eva VIu et al., “The combination of chronic myeloid leukemia and multiple myeloma in one patient,” Voprosy Onkologii, vol. 59, no. 2, pp. 103–110, 2013, in Russian. View at: Google Scholar
  19. L. Ragupathi, V. Najfeld, A. Chari, B. Petersen, S. Jagannath, and J. Mascarenhas, “A case report of chronic myelogenous leukemia in a patient with multiple myeloma and a review of the literature,” Clinical Lymphoma Myeloma and Leukemia, vol. 13, no. 2, pp. 175–179, 2013. View at: Publisher Site | Google Scholar
  20. J. Maerki, G. Katava, D. Siegel, J. Silberberg, and P. K. Bhattacharyya, “Unusual case of simultaneous presentation of plasma cell myeloma, chronic myelogenenous leukemia, and Jak2 positive myeloproliferative disorder,” Case Reports in Hematology, vol. 2014, Article ID 738428, 6 pages, 2014. View at: Publisher Site | Google Scholar
  21. S. Alsidawi, A. Ghose, J. Qualtieri, and N. Radhakrishnan, “A case of multiple myeloma with metachronous chronic myeloid leukemia treated successfully with bortezomib, dexamethasone, and dasatinib,” Case Reports in Oncological Medicine, vol. 2014, Article ID 962526, 4 pages, 2014. View at: Publisher Site | Google Scholar
  22. I. Pessach, V. Bartzis, T. Tzenou et al., “Multiple myeloma and chronic myelogenous leukemia; an uncommon coexistence in 2 patients, with literature review,” Annals of Hematology and Oncology, vol. 2, p. 1030, 2015. View at: Google Scholar
  23. S. Ahn, J. S. Park, J. H. Han et al., “A rare case of chronic myelogenous leukemia and plasma cell myeloma in the same patient,” Annals of Laboratory Medicine, vol. 35, no. 3, pp. 370–372, 2015. View at: Publisher Site | Google Scholar
  24. D. Wolleschak and F. H. Heidel, “Chronic myelogenous leukemia evolving after treatment of multiple myeloma,” Blood, vol. 128, no. 1, p. 146, 2016. View at: Publisher Site | Google Scholar
  25. N. Ali, P. V. Pickens, and H. E. Auerbach, “Immunoglobulin D multiple myeloma, plasma cell leukemia and chronic myelogenous leukemia in a single patient treated simultaneously with lenalidomide, bortezomib, dexamethasone and imatinib,” Hematology Reports, vol. 8, no. 1, p. 6295, 2016. View at: Publisher Site | Google Scholar
  26. A. Palumbo, S. Bringhen, S. K. Kumar et al., “Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data,” The Lancet Oncology, vol. 15, no. 3, pp. 333–342, 2014. View at: Publisher Site | Google Scholar
  27. D. Verma, H. M. Kantarjian, D. Jones et al., “Chronic myeloid leukemia (CML) with P190BCR-ABL: analysis of characteristics, outcomes, and prognostic significance,” Blood, vol. 114, no. 11, pp. 2232–2235, 2009. View at: Publisher Site | Google Scholar

Copyright © 2018 Kosuke Miki et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.